1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Enforcement Roundup: Daniel Chapter One, Peanut Corp. Of America

Final chapter for Daniel Chapter One owner; prison sentence for head of salmonella-tainted peanut firm.

James Feijo, owner and operator of [Daniel Chapter One], a dietary supplement marketer that incurred FDA and the Federal Trade Commission enforcement, faces a potential prison sentence after pleading guilty to failing to pay more than $218,000 in employment taxes to the Internal Revenue Service. The Department of Justice on Sept. 15 said Feijo, 68, also pleaded guilty in federal court in Providence, R.I., to marketing and selling products making unapproved claims as cancer mitigation and treatment options. Separately, the Providence firm, which included a home-based church run by Feijo and his wife Trish Feijo, turned to the Supreme Court in 2011 after a lower court upheld FTC's order that the firm made misleading and unsubstantiated claims, including curing cancer, for its shark cartilage and herbal products. The high court declined to hear Feijo’s argument that FTC overstepped its legal authority with its enforcement action, which required the firm to notify customers it did not have sufficient evidence to support the claim Also see "Herbal Firm Denied Supreme Court Hearing Over Cancer Claim" - Pink Sheet, 30 May, 2011.. Feijo’s sentencing is scheduled for Jan. 12, DoJ said.

The former head of Peanut Corporation of America was sentenced to more than 27 years in prison for convictions on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.

Payment Cap Not Always Solution For Unaffordable Drugs, Maryland PDAB Director Says

 
• By Cathy Kelly

The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.

Future Of US FDA’s Diversity Action Plan Guidance ‘Up In The Air’ As Statutory Deadline Looms

 
• By Sue Sutter

A 26 June deadline looms for the final guidance even though a draft guidance was removed from the agency’s website to comply with President Trump’s gender ideology executive order. The concepts underpinning the guidance are still relevant, legal experts say.

Pink Sheet Podcast: Prasad Staying Out Of Application Reviews, US FDA Proposed Budget Cuts

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss CBER Director Vinay Prasad’s expectation to stay out of routine application decisions, despite the agency’s top-down leadership approach, and the extent of proposed FDA budget cuts.

More from North America

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By Kate Rawson

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.